Table 3 Flow cytometry data for different phenotypic biomarkers from CD4 or CD8 T cells with absolute changes and fold-changes over baseline control samples at 3- (Table 3a) and 6-month (Table 3b) post ipilimumab with p-values for the differences shown

a. Statistical analysis of changes in biomarkers at 3 months

%-ICOS-CD4

25

13.00 (1.15, 20.69)

<.0001

1.35 (0.23, 3.62)

<.0001

%-ICOS-CD8

25

4.19 (2.07, 7.75)

<.0001

2.90 (1.25, 6.72)

<.0001

%-Ki67-CD4

24

3.62 (0.74, 6.94)

<.0001

1.50 (0.18, 2.64)

<.0001

%-Ki67-CD8

24

1.49 (−0.10, 4.86)

0.0009

0.54 (−0.03, 2.20)

0.0003

%-CCR7-CD8

25

−3.98 (−11.40, 1.30)

0.0122

−0.14 (−0.27, 0.04)

0.018

%-CD25-CD8

25

−1.60 (−5.68, -0.70)

<.0001

−0.42 (−0.56, -0.25)

<.0001

b. Statistical analysis of changes in biomarkers at 6 months

%-ICOS-CD4

37

9.45 (3.13, 14.57)

<.0001

1.66 (0.70, 2.42)

<.0001

%-ICOS-CD8

37

3.07 (1.62, 5.36)

<.0001

1.34 (0.63, 3.30)

<.0001

%-Ki67-CD4

35

2.33 (1.37, 6.97)

<.0001

0.87 (0.29, 2.12)

<.0001

%-Ki67-CD8

36

1.88 (0.13, 4.91)

0.0004

0.55 (0.04, 1.52)

<.0001

%-Gata3-CD4

28

3.76 (0.28, 8.04)

0.0004

0.94 (−0.01, 1.62)

<.0001

%-Gata3-CD8

28

2.07 (0.59, 4.02)

0.0006

0.59 (0.09, 1.23)

<.0001

%-CCR7-CD4

37

−2.90 (−6.80, -0.40)

0.0017

−0.03 (−0.09, -0.01)

0.006